International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; World Health Organization; Scheduling Recommendations; Dronabinol (delta-9 tetrahydrocannabinol) and Its Stereoisomers; Cannabis, Cannabis Resin, Extracts and Tinctures; Cannabidiol Preparations; and Pharmaceutical Preparations of Cannabis; Reopening of the Comment Period, 45501-45502 [2019-18714]

Download as PDF Federal Register / Vol. 84, No. 168 / Thursday, August 29, 2019 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2019–N–0767] International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; World Health Organization; Scheduling Recommendations; Dronabinol (delta-9 tetrahydrocannabinol) and Its Stereoisomers; Cannabis, Cannabis Resin, Extracts and Tinctures; Cannabidiol Preparations; and Pharmaceutical Preparations of Cannabis; Reopening of the Comment Period AGENCY: Food and Drug Administration, HHS. Notice; reopening of the comment period. ACTION: The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the notice entitled ‘‘International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; World Health Organization; Scheduling Recommendations; Dronabinol (delta-9 tetrahydrocannabinol) and its Stereoisomers; Cannabis, Cannabis Resin, Extracts and Tinctures; Cannabidiol Preparations; and Pharmaceutical Preparations of Cannabis’’ that appeared in the Federal Register of March 1, 2019. The Agency is taking this action to allow interested persons additional time to submit comments. SUMMARY: FDA is reopening the comment period for the notice published on March 1, 2019 (84 FR 7064). Submit either electronic or written comments by September 30, 2019. ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before September 30, 2019. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of September 30, 2019. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. khammond on DSKBBV9HB2PROD with NOTICES DATES: Electronic Submissions Submit electronic comments in the following way: VerDate Sep<11>2014 17:00 Aug 28, 2019 Jkt 247001 • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2019–N–0767 for ‘‘International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; World Health Organization; Scheduling Recommendations; Dronabinol (delta-9 tetrahydrocannabinol) and its Stereoisomers; Cannabis, Cannabis Resin, Extracts and Tinctures; Cannabidiol Preparations; and Pharmaceutical Preparations of Cannabis.’’ Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 45501 made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/ fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: James Hunter, Center for Drug Evaluation and Research, Controlled Substance Staff, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 5150, Silver Spring, MD 20993–0002, 301–796–3156, james.hunter@fda.hhs.gov. SUPPLEMENTARY INFORMATION: In the Federal Register of March 1, 2019 (84 FR 7064), FDA published a notice with a 14-day comment period to request comments on the notice entitled ‘‘International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; World Health Organization; Scheduling Recommendations; Dronabinol (delta-9 tetrahydrocannabinol) and its Stereoisomers; Cannabis, Cannabis Resin, Extracts and Tinctures; Cannabidiol Preparations; and Pharmaceutical Preparations of E:\FR\FM\29AUN1.SGM 29AUN1 45502 Federal Register / Vol. 84, No. 168 / Thursday, August 29, 2019 / Notices Cannabis.’’ FDA is reopening the comment period until September 30, 2019. The Agency believes that an additional 30 days will allow adequate time for interested persons to submit comments. When the notice was initially published, FDA noted the need for a shortened time period for the submission of comments to ensure that the U.S. Department of Health and Human Services may in timely fashion carry out the required action and be responsive to the United Nations. FDA also noted that if voting on the cannabis-related recommendations was deferred to a later date, the comment period would reopen. The Bureau of the 62nd Commission on Narcotic Drugs decided to postpone the voting on the cannabis-related recommendations by adopting decision 62/14 (available at: https://www.unodc.org/documents/ commissions/CND/Drug_Resolutions/ 2010-2019/2019/Decisions/CND_ Decision_62_14.pdf). Therefore, FDA is reopening the comment period to allow interested persons an additional 30 days to comment. Dated: August 26, 2019. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2019–18714 Filed 8–28–19; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Agency Information Collection Activities: Submission to OMB for Review and Approval; Information Collection Request Title: Forms for Use With Applications to the Maternal and Child Health Bureau Research and Training Grants, New Health Resources and Services Administration (HRSA), Department of Health and Human Services. ACTION: Notice. AGENCY: In compliance with of the Paperwork Reduction Act of 1995, HRSA has submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. DATES: Comments on this ICR must be received no later than September 30, 2019. SUMMARY: Submit your comments to paperwork@hrsa.gov or mail the HRSA Information Collection Clearance Officer, Room 14N136B, 5600 Fishers Lane, Rockville, Maryland 20857. FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and draft instruments, email paperwork@hrsa.gov or call Lisa Wright-Solomon, the HRSA Information Collection Clearance Officer at (301) 443–1984. SUPPLEMENTARY INFORMATION: When submitting comments or requesting information, please include the ICR title for reference. Information Collection Request Title: Forms for Use with Applications for the Maternal and Child Health Bureau Research and Training Grants, OMB No. 0906–xxxx—New. Abstract: HRSA proposes to collect information in conjunction with applications for Maternal and Child Health Bureau (MCHB) grants that describes the qualifications of proposed researchers and the description of expected research participants. This is in compliance with the Social Security Act, Title V, § 501(a)(2) (42 U.S.C. 701(a)(2)), as amended, and the Public Health Service Act, § 399BB(f), (42 U.S.C. 280i–1(f)) as amended by the Autism CARES Act of 2014 (Pub. L. 113–157). Need and Proposed Use of the Information: In MCHB’s research and training grant programs, the applicants ADDRESSES: will complete the Biographical Sketch form to summarize the qualifications of each key personnel on their proposed research team. The grant reviewers will utilize this information to assess the capabilities of the research team to carry out the planned research project. Applicants will also complete the Inclusion Enrollment form to summarize their expected population of research study participants at the time of submission of their proposal. This information supports decision-making as part of the annual Noncompeting Continuation Award process. Monitoring inclusion enrollment is an important component of ensuring demographic diversity (race, ethnicity, and gender) among research study participants in MCHB’s research grant portfolio. This allows MCHB to determine to what extent individuals of different backgrounds are participating in MCHB research and training programs. A 60-day notice was published in the Federal Register on September 13, 2018, vol. 83, No. 178; pp. 46504–05. There were no public comments. Likely Respondents: Potential applicants to HRSA’s MCHB research and training programs. Burden Statement: Burden in this context means the time expended by persons to generate, maintain, retain, disclose or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install, and utilize technology and systems for the purpose of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the table below. TOTAL ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents khammond on DSKBBV9HB2PROD with NOTICES Form name Biographical Sketch for MCHB research and training grant applicants ......................................................................... PHS Inclusion Enrollment form for MCHB research and training grant applications ................................................ Total .............................................................................. VerDate Sep<11>2014 17:00 Aug 28, 2019 Jkt 247001 PO 00000 Frm 00040 Fmt 4703 Number of responses per respondent Total responses Average burden per response (in hours) Total burden hours 200 5 1,000 2.0 2,000 200 1 200 0.5 100 400 ........................ 1,200 ........................ 2,100 Sfmt 4703 E:\FR\FM\29AUN1.SGM 29AUN1

Agencies

[Federal Register Volume 84, Number 168 (Thursday, August 29, 2019)]
[Notices]
[Pages 45501-45502]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-18714]



[[Page 45501]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-0767]


International Drug Scheduling; Convention on Psychotropic 
Substances; Single Convention on Narcotic Drugs; World Health 
Organization; Scheduling Recommendations; Dronabinol (delta-9 
tetrahydrocannabinol) and Its Stereoisomers; Cannabis, Cannabis Resin, 
Extracts and Tinctures; Cannabidiol Preparations; and Pharmaceutical 
Preparations of Cannabis; Reopening of the Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; reopening of the comment period.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or the Agency) is 
reopening the comment period for the notice entitled ``International 
Drug Scheduling; Convention on Psychotropic Substances; Single 
Convention on Narcotic Drugs; World Health Organization; Scheduling 
Recommendations; Dronabinol (delta-9 tetrahydrocannabinol) and its 
Stereoisomers; Cannabis, Cannabis Resin, Extracts and Tinctures; 
Cannabidiol Preparations; and Pharmaceutical Preparations of Cannabis'' 
that appeared in the Federal Register of March 1, 2019. The Agency is 
taking this action to allow interested persons additional time to 
submit comments.

DATES: FDA is reopening the comment period for the notice published on 
March 1, 2019 (84 FR 7064). Submit either electronic or written 
comments by September 30, 2019.

ADDRESSES: You may submit comments as follows. Please note that late, 
untimely filed comments will not be considered. Electronic comments 
must be submitted on or before September 30, 2019. The https://www.regulations.gov electronic filing system will accept comments until 
11:59 p.m. Eastern Time at the end of September 30, 2019. Comments 
received by mail/hand delivery/courier (for written/paper submissions) 
will be considered timely if they are postmarked or the delivery 
service acceptance receipt is on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2019-N-0767 for ``International Drug Scheduling; Convention on 
Psychotropic Substances; Single Convention on Narcotic Drugs; World 
Health Organization; Scheduling Recommendations; Dronabinol (delta-9 
tetrahydrocannabinol) and its Stereoisomers; Cannabis, Cannabis Resin, 
Extracts and Tinctures; Cannabidiol Preparations; and Pharmaceutical 
Preparations of Cannabis.'' Received comments, those filed in a timely 
manner (see ADDRESSES), will be placed in the docket and, except for 
those submitted as ``Confidential Submissions,'' publicly viewable at 
https://www.regulations.gov or at the Dockets Management Staff between 
9 a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: James Hunter, Center for Drug 
Evaluation and Research, Controlled Substance Staff, Food and Drug 
Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 5150, Silver 
Spring, MD 20993-0002, 301-796-3156, [email protected].

SUPPLEMENTARY INFORMATION: In the Federal Register of March 1, 2019 (84 
FR 7064), FDA published a notice with a 14-day comment period to 
request comments on the notice entitled ``International Drug 
Scheduling; Convention on Psychotropic Substances; Single Convention on 
Narcotic Drugs; World Health Organization; Scheduling Recommendations; 
Dronabinol (delta-9 tetrahydrocannabinol) and its Stereoisomers; 
Cannabis, Cannabis Resin, Extracts and Tinctures; Cannabidiol 
Preparations; and Pharmaceutical Preparations of

[[Page 45502]]

Cannabis.'' FDA is reopening the comment period until September 30, 
2019. The Agency believes that an additional 30 days will allow 
adequate time for interested persons to submit comments.
    When the notice was initially published, FDA noted the need for a 
shortened time period for the submission of comments to ensure that the 
U.S. Department of Health and Human Services may in timely fashion 
carry out the required action and be responsive to the United Nations. 
FDA also noted that if voting on the cannabis-related recommendations 
was deferred to a later date, the comment period would reopen. The 
Bureau of the 62nd Commission on Narcotic Drugs decided to postpone the 
voting on the cannabis-related recommendations by adopting decision 62/
14 (available at: https://www.unodc.org/documents/commissions/CND/Drug_Resolutions/2010-2019/2019/Decisions/CND_Decision_62_14.pdf). 
Therefore, FDA is reopening the comment period to allow interested 
persons an additional 30 days to comment.

    Dated: August 26, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-18714 Filed 8-28-19; 8:45 am]
BILLING CODE 4164-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.